若您需要咨询产品或有任何技术问题,请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

IWR-1-endo

WNT通路抑制剂;AXIN2稳定剂

产品号 #(选择产品)

产品号 #72562_C

WNT通路抑制剂;AXIN2稳定剂

总览

IWR-1-endo 通过阻断细胞内的 WNT/β-catenin 通路报告基因反应,有效抑制 WNT 信号传导,IC50 值为 180 nM(Chen et al.)。它通过稳定破坏复合物成员 AXIN2,抑制 WNT 诱导的 β-catenin 积累(Chen et al.)。

维持和自我更新
·与 CHIR99021 联合使用,可促进人胚胎干细胞和小鼠上皮干细胞的自我更新并维持其多能性(Kim et al.)。

分化
·促进已通过添加激活素A和/或骨形态发生蛋白4 (BMP4) 诱导向中胚层分化的人多能干细胞 (PSC) 向心肌细胞的分化(Ren et al.; Willems et al.)
·诱导人 PSC 衍生的 II 型肺泡上皮细胞 (AETII) 向 AETI 细胞的分化 (Ghaedi et al.)。

细胞类型
气道细胞,心肌细胞,PSC衍生,多能干细胞
 
种属
人,小鼠,非人灵长类,其它细胞系,大鼠
 
应用
分化,扩增,培养
 
研究领域
上皮细胞研究,干细胞生物学
 
CAS 编号
1127442-82-3
 
化学式
C₂₅H₁₉N₃O₃
 
纯度
≥98%
 
通路
WNT
 
靶点
Axin
 

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明,或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Product Name
IWR-1-endo
Catalog #
72564, 72562
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
IWR-1-endo
Catalog #
72564, 72562
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计,适用于工作流程中的高亮阶段。探索这些工作流程,了解更多我们为各研究领域提供的其他配套产品。

相关材料与文献

技术资料 (3)

文献 (8)

Human iPS cell-derived alveolar epithelium repopulates lung extracellular matrix. Ghaedi M et al. The Journal of clinical investigation 2013 NOV

Abstract

The use of induced pluripotent stem cells (iPSCs) has been postulated to be the most effective strategy for developing patient-specific respiratory epithelial cells, which may be valuable for lung-related cell therapy and lung tissue engineering. We generated a relatively homogeneous population of alveolar epithelial type II (AETII) and type I (AETI) cells from human iPSCs that had phenotypic properties similar to those of mature human AETII and AETI cells. We used these cells to explore whether lung tissue can be regenerated in vitro. Consistent with an AETII phenotype, we found that up to 97% of cells were positive for surfactant protein C, 95% for mucin-1, 93% for surfactant protein B, and 89% for the epithelial marker CD54. Additionally, exposing induced AETII to a Wnt/β-catenin inhibitor (IWR-1) changed the iPSC-AETII-like phenotype to a predominantly AETI-like phenotype. We found that of induced AET1 cells, more than 90% were positive for type I markers, T1α, and caveolin-1. Acellular lung matrices were prepared from whole rat or human adult lungs treated with decellularization reagents, followed by seeding these matrices with alveolar cells derived from human iPSCs. Under appropriate culture conditions, these progenitor cells adhered to and proliferated within the 3D lung tissue scaffold and displayed markers of differentiated pulmonary epithelium.
Modulation of β-catenin function maintains mouse epiblast stem cell and human embryonic stem cell self-renewal. Kim H et al. Nature communications 2013 JAN

Abstract

Wnt/β-catenin signalling has a variety of roles in regulating stem cell fates. Its specific role in mouse epiblast stem cell self-renewal, however, remains poorly understood. Here we show that Wnt/β-catenin functions in both self-renewal and differentiation in mouse epiblast stem cells. Stabilization and nuclear translocation of β-catenin and its subsequent binding to T-cell factors induces differentiation. Conversely, retention of stabilized β-catenin in the cytoplasm maintains self-renewal. Cytoplasmic retention of β-catenin is effected by stabilization of Axin2, a downstream target of β-catenin, or by genetic modifications to β-catenin that prevent its nuclear translocation. We also find that human embryonic stem cell and mouse epiblast stem cell fates are regulated by β-catenin through similar mechanisms. Our results elucidate a new role for β-catenin in stem cell self-renewal that is independent of its transcriptional activity and will have broad implications in understanding the molecular regulation of stem cell fate.
Small molecule Wnt inhibitors enhance the efficiency of BMP-4-directed cardiac differentiation of human pluripotent stem cells. Ren Y et al. Journal of molecular and cellular cardiology 2011 SEP

Abstract

Human induced pluripotent stem (iPS) cells potentially provide a unique resource for generating patient-specific cardiomyocytes to study cardiac disease mechanisms and treatments. However, existing approaches to cardiomyocyte production from human iPS cells are inefficient, limiting the application of iPS cells in basic and translational cardiac research. Furthermore, strategies to accurately record changes in iPS cell-derived cardiomyocyte action potential duration (APD) are needed to monitor APD-related cardiac disease and for rapid drug screening. We examined whether modulation of the bone morphogenetic protein 4 (BMP-4) and Wnt/β-catenin signaling pathways could induce efficient cardiac differentiation of human iPS cells. We found that early treatment of human iPS cells with BMP-4 followed by late treatment with small molecule Wnt inhibitors led to a marked increase in production of cardiomyocytes compared to existing differentiation strategies. Using immunocytochemical staining and real-time intracellular calcium imaging, we showed that these induced cardiomyocytes expressed typical sarcomeric markers, exhibited normal rhythmic Ca(2+) transients, and responded to both β-adrenergic and electric stimulation. Furthermore, human iPS cell-derived cardiomyocytes demonstrated characteristic changes in action potential duration in response to cardioactive drugs procainamide and verapamil using voltage-sensitive dye-based optical recording. Thus, modulation of the BMP-4 and Wnt signaling pathways in human iPS cells leads to highly efficient production of cardiomyocytes with typical electrophysiological function and pharmacologic responsiveness. The use of human iPS cell-derived cardiomyocytes and the application of calcium- and voltage-sensitive dyes for the direct, rapid measurement of iPS cell-derived cardiomyocyte activity promise to offer attractive platforms for studying cardiac disease mechanisms and therapeutics.

更多信息

更多信息
种属 Human, Mouse, Non-Human Primate, Other, Rat
Cas Number 1127442-82-3
Chemical Formula C₂₅H₁₉N₃O₃
纯度 ≥ 98%
Target Axin
Pathway WNT
质量保证:

产品仅供研究使用,不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息,请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.